Screener
Nuvation Bio NUVB Operating Income
Discontinued — last reported Q2 '26
Operating Income at other companies
Other financials
Where this comes from
Reported directly by Nuvation Bio in its filing.
Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.
The source filing: Nuvation Bio’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 6:55 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-336646
| Line item | For the Three Months Ended June 30, 2026 | For the Three Months Ended June 30, 2025 | For the Six Months Ended June 30, 2026 | For the Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Research and development | 30,661 | 27,362 | 65,708 | 51,963 |
| Selling, general and administrative | 42,591 | 38,484 | 80,900 | 73,877 |
| Total costs and expenses | 82,723 | 68,422 | 162,070 | 130,510 |
| Loss from operations | (51,036) | (63,589) | (47,155) | (122,593) |
| Other income (expense): | ||||
| Interest income | 4,596 | 4,780 | 9,704 | 10,101 |
| Interest expense | (6,759) | (421) | (13,467) | (475) |
| Investment advisory fees | (184) | (182) | (379) | (385) |
Item 1. Financial Statements.
FAQ
- What is Nuvation Bio's operating income?
- Nuvation Bio (NUVB) reported operating income of -$51.04M in Q2 2026.
- How has Nuvation Bio's operating income changed year-over-year?
- Nuvation Bio's operating income increased by 19.7% year-over-year, from -$63.59M to -$51.04M.
- What is the long-term trend for Nuvation Bio's operating income?
- Over 4 years (2021 to 2025), Nuvation Bio's operating income has grown at a 22.9% compound annual growth rate (CAGR), from -$93.32M to -$213.06M.
- What does operating income mean?
- Gross profit minus all operating expenses (SG&A, R&D, D&A). Measures the profit from core business operations before interest, taxes, and non-operating items.
Ask your AI about Nuvation Bio's operating income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude